Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$804 Mln
P/E Ratio
--
P/B Ratio
7.22
Industry P/E
--
Debt to Equity
0
ROE
-0.38 %
ROCE
--
Div. Yield
0 %
Book Value
1.31
EPS
-0.55
CFO
$-159.94 Mln
EBITDA
$-272.65 Mln
Net Profit
$-255.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
| -12.29 | -1.98 | -10.20 | 176.25 | -0.73 | 22.82 | 18.54 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
| 15.23 | 0.54 | -46.60 | 221.11 | 108.49 | 66.03 | -51.36 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the... treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. Read more
President, CEO, Secretary & Director
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
President, CEO, Secretary & Director
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Anavex Life Sciences Corp (AVXL) stood at $ 137 Mln as on 31-Dec-24
The share price of Anavex Life Sciences Corp (AVXL) is $9.42 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Anavex Life Sciences Corp (AVXL) has given a return of -0.73% in the last 3 years.
Anavex Life Sciences Corp (AVXL) has a market capitalisation of $ 804 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Anavex Life Sciences Corp (AVXL) is 7.22 times as on 25-Apr-2025, a 215% premium to its peers’ median range of 2.29 times.
Since, TTM earnings of Anavex Life Sciences Corp (AVXL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Anavex Life Sciences Corp (AVXL) and enter the required number of quantities and click on buy to purchase the shares of Anavex Life Sciences Corp (AVXL).
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
The CEO & director of Dr. Christopher U. Missling M.B.A., M.S., Ph.D.. is Anavex Life Sciences Corp (AVXL), and CFO & Sr. VP is Dr. Christopher U. Missling M.B.A., M.S., Ph.D..
There is no promoter pledging in Anavex Life Sciences Corp (AVXL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Anavex Life Sciences Corp. (AVXL) | Ratios |
|---|---|
|
Return on equity(%)
|
-38.63
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Anavex Life Sciences Corp (AVXL) was $0 Mln.
$-0.03
(
